| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $4,907,598 | 10 | 100 |
| Chauche Thierry | Chief Financial Officer | 0 | $0 | 1 | $7,033 | $-7,033 |
| Martins Eduardo Bruno | Chief Medical Officer | 0 | $0 | 1 | $19,511 | $-19,511 |
| Rozek Elizabeth | Chief Legal & Admin. Officer | 0 | $0 | 2 | $95,887 | $-95,887 |
| Happel David | President & CEO | 0 | $0 | 2 | $561,933 | $-561,933 |
| Kemble George | Executive Chairman | 0 | $0 | 4 | $4.22M | $-4.22M |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; …
Over the last 12 months, insiders at Sagimet Biosciences Inc. have bought $0 and sold $4.91M worth of Sagimet Biosciences Inc. stock.
On average, over the past 5 years, insiders at Sagimet Biosciences Inc. have bought $271,865 and sold $1.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,100 shares for transaction amount of $63,731 was made by Happel David (President & CEO) on 2024‑03‑26.
| 2026-08-14 | Sale | Kemble George | director | 350,987 0.6409% | $10.23 | $3.59M | -3.03% | |
| 2026-08-11 | Sale | Kemble George | director | 20,206 0.0648% | $9.95 | $201,147 | +7.25% | |
| 2026-07-20 | Sale | Happel David | President & CEO | 64,051 0.2131% | $7.76 | $497,068 | +36.03% | |
| 2026-07-20 | Sale | Rozek Elizabeth | Chief Legal & Admin. Officer | 10,545 0.0351% | $7.76 | $81,832 | +36.03% | |
| 2026-07-20 | Sale | Kemble George | director | 18,844 0.0602% | $7.46 | $140,529 | +36.03% | |
| 2026-02-10 | Sale | Happel David | President & CEO | 12,101 0.0371% | $5.36 | $64,865 | +30.50% | |
| 2026-02-10 | Sale | Rozek Elizabeth | Chief Legal & Admin. Officer | 2,622 0.008% | $5.36 | $14,054 | +30.50% | |
| 2026-02-10 | Sale | Martins Eduardo Bruno | Chief Medical Officer | 3,640 0.0112% | $5.36 | $19,511 | +30.50% | |
| 2026-02-10 | Sale | Chauche Thierry | Chief Financial Officer | 1,312 0.004% | $5.36 | $7,033 | +30.50% | |
| 2025-11-20 | Sale | Kemble George | Executive Chairman | 37,688 0.1287% | $7.69 | $289,979 | -4.88% | |
| 2025-07-21 | Sale | Happel David | President & CEO | 65,478 0.2208% | $9.13 | $598,115 | -22.31% | |
| 2025-07-21 | Sale | Rozek Elizabeth | General Counsel and CCO | 10,780 0.0364% | $9.13 | $98,471 | -22.31% | |
| 2025-07-21 | Sale | Martins Eduardo Bruno | Chief Medical Officer | 8,277 0.0279% | $9.13 | $75,607 | -22.31% | |
| 2024-07-23 | Sale | Kemble George | Executive Chairman | 23,625 0.0429% | $3.17 | $74,830 | +24.92% | |
| 2024-07-19 | Sale | Rozek Elizabeth | General Counsel and CCO | 10,914 0.0194% | $3.10 | $33,830 | +31.39% | |
| 2024-07-19 | Sale | Kemble George | Executive Chairman | 14,062 0.025% | $3.10 | $43,605 | +31.39% | |
| 2024-07-19 | Sale | Martins Eduardo Bruno | Chief Medical Officer | 8,357 0.0148% | $3.10 | $25,910 | +31.39% | |
| 2024-03-26 | Happel David | President & CEO | 12,100 0.0365% | $5.27 | $63,731 | -19.50% | ||
| 2023-07-18 | Sale | NEW ENTERPRISE ASSOCIATES 13 LP | 10 percent owner | 662 0.0061% | $16.00 | $10,592 | -66.48% | |
| 2023-07-18 | NEW ENTERPRISE ASSOCIATES 13 LP | 10 percent owner | 30,000 0.275% | $16.00 | $480,000 | -66.48% |
| Happel David | President & CEO | 741570 2.276% | $7.38M | 1 | 3 | <0.0001% |
| NEW ENTERPRISE ASSOCIATES 13 LP | 10 percent owner | 3850275 11.8173% | $38.31M | 1 | 1 |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$2,471,510 | 19 | 17.33% | $334.18M | |
$10,399,379 | 13 | 13.60% | $302.03M | |
$57,263,116 | 11 | -8.37% | $386.95M |
| Increased Positions | 54 | +76.06% | 4M | +32.85% |
| Decreased Positions | 27 | -38.03% | 2M | -19.14% |
| New Positions | 27 | New | 2M | New |
| Sold Out Positions | 10 | Sold Out | 957,045 | Sold Out |
| Total Postitions | 98 | +38.03% | 14M | +13.72% |
| Woodline Partners Lp | $8,993.00 | 4.84% | 1.5M | -1M | -41.18% | 2025-09-30 |
| Blue Owl Capital Holdings Lp | $7,957.00 | 4.29% | 1.33M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $7,207.00 | 3.88% | 1.2M | +49,375 | +4.28% | 2025-09-30 |
| Baker Bros. Advisors Lp | $5,708.00 | 3.07% | 952,996 | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $4,650.00 | 2.5% | 776,377 | +700,737 | +926.41% | 2025-09-30 |
| Hhlr Advisors, Ltd. | $4,342.00 | 2.34% | 724,800 | 0 | 0% | 2025-09-30 |
| Siren, L.L.C. | $4,341.00 | 2.34% | 724,771 | 0 | 0% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $4,200.00 | 2.26% | 701,241 | +557,393 | +387.49% | 2025-09-30 |
| Blackrock, Inc. | $3,670.00 | 1.98% | 612,717 | +129,634 | +26.84% | 2025-09-30 |
| Schonfeld Strategic Advisors Llc | $3,137.00 | 1.69% | 523,774 | +430,644 | +462.41% | 2025-09-30 |